pexmetinib
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00916227)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
- Tyrosine-protein kinase TIE-2INHIBITOR
TEK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1- Mol. weight
- 556.64 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3991932 ↗
- ChEMBLCHEMBL3545297 ↗
Also known as
- arry-614
- arry-614
- arry-614
- arry-614
- pexmetinib
- pexmetinib
- pexmetinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01496495 | Phase 1 | Jan 1, 2012 | Array BioPharma |
| NCT00916227 | Phase 1 | Jun 1, 2009 | Array BioPharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Array BioPharma | For profit | 2 | 2 | 1 | 2009 |
1 organizations
Page 1 / 1